Targeting the tumour vasculature in mesothelioma

被引：3

作者：

Fennell, Dean A. ^{[1
,2
]}

机构：

[1] Univ Leicester, Canc Res UK Ctr, Leicester LE1 9HN, Leics, England

[2] Univ Hosp Leicester NHS Trust, Leicester LE1 9HN, Leics, England

来源：

LANCET ONCOLOGY | 2018年 / 19卷 / 06期

关键词：

MALIGNANT PLEURAL MESOTHELIOMA; DOUBLE-BLIND; OPEN-LABEL; TRIAL; PHASE-3;

D O I：

10.1016/S1470-2045(18)30248-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：723 / 724

页数：3

共 10 条

[1] Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial [J].

Alley, Evan W. ;

Lopez, Juanita ;

Santoro, Armando ;

Morosky, Anne ;

Saraf, Sanatan ;

Piperdi, Bilal ;

van Brummelen, Emilie .

LANCET ONCOLOGY, 2017, 18 (05) :623-630

[2]

[Anonymous], 2010, DRUG NEWS PERSPECT, V23, P395

[3] Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration [J].

Curnis, F ;

Sacchi, A ;

Corti, A .

JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (04) :475-482

[4] NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 [J].

Gregorc, Vanesa ;

Gaafar, Rabab M. ;

Favaretto, Adolfo ;

Grossi, Francesco ;

Jassem, Jacek ;

Polychronis, Andreas ;

Bidoli, Paolo ;

Tiseo, Marcello ;

Shah, Riyaz ;

Taylor, Paul ;

Novello, Silvia ;

Muzio, Alberto ;

Bearz, Alessandra ;

Greillier, Laurent ;

Fontana, Floriana ;

Salini, Giulia ;

Lambiase, Antonio ;

O'Brien, Mary .

LANCET ONCOLOGY, 2018, 19 (06) :799-811

[5] Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma [J].

Gregorc, Vanesa ;

Zucali, Paolo A. ;

Santoro, Armando ;

Ceresoli, Giovanni L. ;

Citterio, Giovanni ;

De Pas, Tommaso M. ;

Zilembo, Nicoletta ;

De Vincenzo, Fabio ;

Simonelli, Matteo ;

Rossoni, Gilda ;

Spreafico, Anna ;

Vigano, Maria Grazia ;

Fontana, Floriana ;

De Braud, Filippo G. ;

Bajetta, Emilio ;

Caligaris-Cappio, Federico ;

Bruzzi, Paolo ;

Lambiase, Antonio ;

Bordignon, Claudio .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) :2604-2611

[6] Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial [J].

Grosso, Federica ;

Steele, Nicola ;

Novello, Silvia ;

Nowak, Anna K. ;

Popat, Sanjay ;

Greillier, Laurent ;

John, Thomas ;

Leighl, Natasha B. ;

Reck, Martin ;

Taylor, Paul ;

Planchard, David ;

Sorensen, Jens Benn ;

Socinski, Mark A. ;

von Wangenheim, Ute ;

Loembe, Arsene Bienvenu ;

Barrueco, Jose ;

Morsli, Nassim ;

Scagliotti, Giorgio .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31) :3591-+

[7] Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial [J].

Krug, Lee M. ;

Kindler, Hedy L. ;

Calvert, Hilary ;

Manegold, Christian ;

Tsao, Anne S. ;

Fennell, Dean ;

Ohman, Ronny ;

Plummer, Ruth ;

Eberhardt, Wilfried E. E. ;

Fukuoka, Kazuya ;

Gaafar, Rabab M. ;

Lafitte, Jean-Jacques ;

Hillerdal, Gunnar ;

Chu, Quincy ;

Buikhuisen, Wieneke A. ;

Lubiniecki, Gregory M. ;

Sun, Xing ;

Smith, Margaret ;

Baas, Paul .

LANCET ONCOLOGY, 2015, 16 (04) :447-456

[8] Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial [J].

Maio, Michele ;

Scherpereel, Arnaud ;

Calabro, Luana ;

Aerts, Joachim ;

Cedres Perez, Susana ;

Bearz, Alessandra ;

Nackaerts, Kristiaan ;

Fennell, Dean A. ;

Kowalski, Dariusz ;

Tsao, Anne S. ;

Taylor, Paul ;

Grosso, Federica ;

Antonia, Scott J. ;

Nowak, Anna K. ;

Taboada, Maria ;

Puglisi, Martina ;

Stockman, Paul K. ;

Kindler, Hedy L. .

LANCET ONCOLOGY, 2017, 18 (09) :1261-1273

[9] Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma A Randomized Clinical Trial [J].

Szlosarek, Peter W. ;

Steele, Jeremy P. ;

Nolan, Luke ;

Gilligan, David ;

Taylor, Paul ;

Spicer, James ;

Lind, Michael ;

Mitra, Sankhasuvra ;

Shamash, Jonathan ;

Phillips, Melissa M. ;

Luong, Phuong ;

Payne, Sarah ;

Hillman, Paul ;

Ellis, Stephen ;

Szyszko, Teresa ;

Dancey, Gairin ;

Butcher, Lee ;

Beck, Stephan ;

Avril, Norbert E. ;

Thomson, Jim ;

Johnston, Amanda ;

Tomsa, Marianne ;

Lawrence, Cheryl ;

Schmid, Peter ;

Crook, Timothy ;

Wu, Bor-Wen ;

Bomalaski, John S. ;

Lemoine, Nicholas ;

Sheaff, Michael T. ;

Rudd, Robin M. ;

Fennell, Dean ;

Hackshaw, Allan .

JAMA ONCOLOGY, 2017, 3 (01) :58-66

[10] Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial [J].

Zalcman, Gerard ;

Mazieres, Julien ;

Margery, Jacques ;

Greillier, Laurent ;

Audigier-Valette, Clarisse ;

Moro-Sibilot, Denis ;

Molinier, Olivier ;

Corre, Romain ;

Monnet, Isabelle ;

Gounant, Valerie ;

Riviere, Frederic ;

Janicot, Henri ;

Gervais, Radj ;

Locher, Chrystele ;

Milleron, Bernard ;

Quan Tran ;

Lebitasy, Marie-Paule ;

Morin, Franck ;

Creveuil, Christian ;

Parienti, Jean-Jacques ;

Scherpereel, Arnaud .

LANCET, 2016, 387 (10026) :1405-1414

← 1 →